Comprehensive Report: Bardoxolone Methyl (DB05983) — A Clinical and Regulatory Post-Mortem

Executive Summary

Bardoxolone methyl (DB05983) is an investigational small molecule that represents a compelling yet cautionary tale in modern drug development. Initially conceived as an anti-neoplastic and anti-inflammatory agent, its trajectory was dramatically altered by the serendipitous observation of improved kidney function in early-phase oncology trials. This finding launched a large-scale, multi-billion-dollar clinical program aimed at treating chronic kidney disease (CKD), a condition with a significant unmet medical need. The drug's mechanism of action, centered on the potent activation of the Nrf2 antioxidant pathway and concurrent inhibition of the pro-inflammatory NF-κB pathway, offered a scientifically elegant rationale for its potential to mitigate the oxidative stress and inflammation that drive CKD progression.

Early and mid-stage clinical trials, most notably the Phase 2 BEAM study, generated considerable optimism by demonstrating statistically significant and substantial increases in estimated glomerular filtration rate (eGFR) in patients with CKD and type 2 diabetes. However, this promise was abruptly curtailed by the premature termination of the pivotal Phase 3 BEACON trial. The study was halted due to an unacceptable increase in serious cardiovascular adverse events, including hospitalizations for heart failure and death, in the bardoxolone methyl arm. Post-hoc analyses attributed these events to drug-induced fluid overload, particularly in patients with pre-existing cardiovascular risk factors.

Despite this major setback, development continued with a focus on rare kidney diseases, culminating in the Phase 3 CARDINAL trial for patients with Alport syndrome. While this trial met its primary "on-treatment" eGFR endpoints, the benefit was largely lost after a brief drug washout period. This outcome failed to convince regulators that the drug provided a durable modification of disease progression, instead suggesting a primarily transient pharmacodynamic or hemodynamic effect. Compounding this were persistent safety concerns, including hepatotoxicity, increased albuminuria, and elevations in blood pressure.

Ultimately, regulatory bodies in both the United States and Europe rejected the drug for Alport syndrome. The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter following a unanimous negative vote by its advisory committee, citing a lack of demonstrated efficacy and an unfavorable benefit-risk profile. Similarly, the marketing application was withdrawn in Europe after the European Medicines Agency (EMA) expressed insurmountable concerns. The final chapter of bardoxolone methyl's development closed in May 2023, when results from the long-term AYAME trial in Japan, while meeting a composite endpoint involving eGFR, showed no benefit on the hard clinical outcome of end-stage kidney disease (ESKD). This definitive lack of translation from a surrogate marker to a meaningful clinical benefit led to the cessation of all ongoing clinical development. The story of bardoxolone methyl serves as a critical case study on the perils of over-reliance on surrogate endpoints, the importance of comprehensive safety characterization, and the complex challenge of targeting fundamental biological pathways in chronically ill patient populations.

Molecular Profile and Physicochemical Properties

Chemical Identity and Nomenclature

Bardoxolone methyl is a semi-synthetic triterpenoid compound, a structural class of molecules derived from natural precursors, in this case, oleanolic acid.[1] As a small molecule intended for oral administration, it has been assigned numerous identifiers across chemical, clinical, and regulatory databases throughout its extensive development history. Its formal chemical name under the International Union of Pure and Applied Chemistry (IUPAC) system is methyl (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylate.[3] The Chemical Abstracts Service (CAS) has assigned it the registry number 218600-53-4, which serves as a unique identifier in scientific literature and chemical inventories.[1]

During its investigation, the compound was known by several synonyms and code names. The most common are CDDO-methyl ester or CDDO-Me, reflecting its chemical nature as the methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO).[1] In the context of its clinical development by Reata Pharmaceuticals and its partners, it was primarily referred to by the code name RTA 402.[1] Other identifiers include the National Service Center number NSC 713200 and the internal code TP-155.[2] For regulatory and database tracking, it is assigned DrugBank ID DB05983 and FDA Unique Ingredient Identifier (UNII) CEG1Q6OGU1.[3] A consolidated list of these key identifiers is provided in Table 1.

Identifier Type	Identifier Value	Source/Issuing Body
Common Name	Bardoxolone methyl	-
DrugBank ID	DB05983	DrugBank
CAS Number	218600-53-4	Chemical Abstracts Service (CAS)
IUPAC Name	methyl (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylate	IUPAC
FDA UNII	CEG1Q6OGU1	FDA Global Substance Registration System (GSRS)
ChEMBL ID	CHEMBL1762621	ChEMBL
NSC Number	713200	National Cancer Institute (NCI) DTP
Code Names	RTA 402, CDDO-Me, CDDO-methyl ester, TP-155	Reata Pharmaceuticals, various research contexts
Synonyms	methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate	Various chemical databases

Structural and Physicochemical Characteristics

The molecular structure of bardoxolone methyl is foundational to its biological activity. Its molecular formula is C32​H43​NO4​, corresponding to an average molecular weight of 505.7 g/mol and a monoisotopic mass of 505.3192 Da.[3] It is structurally derived from oleanolic acid, a naturally occurring pentacyclic triterpenoid, which itself possesses modest anti-inflammatory properties.[10] The synthetic modifications applied to the oleanolic acid scaffold were designed to significantly enhance these biological activities.[10]

Physically, bardoxolone methyl is a white to off-white or light brown solid.[2] It has a reported melting point in the range of 215–223 °C.[2] Its solubility profile is characteristic of a lipophilic molecule; it is soluble in organic solvents such as ethanol (10 mg/mL) and dimethyl sulfoxide (DMSO) (5 mg/mL), but is poorly soluble in aqueous solutions like water or phosphate-buffered saline (PBS).[6] This lipophilicity is reflected in its high calculated partition coefficient (AlogP) of approximately 6.4–6.6, indicating a strong preference for lipid environments over aqueous ones.[8] This property is consistent with its oral bioavailability and likely contributes to its distribution within the body.

For computational chemistry and database indexing, its structure is represented by the following identifiers:

• SMILES: C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)OC [3]
• InChIKey: WPTTVJLTNAWYAO-KPOXMGGZSA-N [3]

From a chemical classification standpoint, bardoxolone methyl belongs to the class of organic compounds known as cyclohexenones.[9] A critical feature of its structure is the presence of two electrophilic α,β-unsaturated carbonyl groups, located on the A and C rings of the triterpenoid backbone.[10] These reactive moieties are essential for the molecule's potent biological activity, as they are capable of undergoing Michael addition reactions with nucleophilic groups on target proteins. This specific chemical reactivity is the molecular basis for its pharmacological mechanism of action.

Core Pharmacology: The Dual Mechanism of Nrf2 Activation and NF-κB Inhibition

The pharmacological profile of bardoxolone methyl is defined by its potent and dualistic modulation of two central signaling pathways that govern cellular responses to stress and inflammation: the Keap1/Nrf2 antioxidant pathway and the NF-κB pro-inflammatory pathway.

Activation of the Keap1/Nrf2 Antioxidant Response Pathway

Bardoxolone methyl is recognized as the most potent inducer of the Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway to have entered clinical development.[4] Nrf2 is a master transcription factor that orchestrates the cellular defense against oxidative and electrophilic stress by regulating the expression of a wide array of cytoprotective genes.[13]

Under normal, unstressed conditions, Nrf2 is kept at low levels in the cytoplasm. Its primary negative regulator is the Kelch-like ECH-associated protein 1 (Keap1), which acts as a substrate adaptor for a Cul3-Rbx1-based E3 ubiquitin ligase complex.[16] Keap1 continuously targets Nrf2 for ubiquitination, marking it for rapid degradation by the proteasome.[16] This constant turnover ensures that the Nrf2-mediated response is tightly controlled and activated only when needed.

The primary mechanism of action of bardoxolone methyl involves the direct disruption of this regulatory system. The α,β-unsaturated carbonyl groups on the bardoxolone methyl molecule act as Michael acceptors, enabling a reversible covalent interaction with the highly reactive thiol groups of specific cysteine residues on Keap1, notably Cys179.[2] This chemical modification of Keap1 induces a conformational change that disrupts the Keap1-Nrf2 interaction, thereby inhibiting the E3 ligase complex's ability to ubiquitinate Nrf2.[15]

With its degradation pathway blocked, Nrf2 is stabilized, allowing it to accumulate in the cytoplasm and subsequently translocate into the nucleus.[2] Once in the nucleus, Nrf2 forms a heterodimer with small Maf (musculoaponeurotic fibrosarcoma) proteins. This Nrf2-Maf complex then binds to specific DNA sequences known as Antioxidant Response Elements (AREs) or Electrophile Responsive Elements (EpREs), which are located in the promoter regions of its target genes.[15] This binding initiates the transcription of a battery of over 200 cytoprotective genes involved in antioxidant defense, detoxification, and metabolic regulation. Key examples of these induced proteins include NAD(P)H:quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), glutathione S-transferases (GSTs), and subunits of glutamate-cysteine ligase, the rate-limiting enzyme in glutathione synthesis.[2] The coordinated upregulation of this genetic program enhances the cell's capacity to neutralize reactive oxygen species (ROS) and detoxify harmful electrophiles, thereby conferring robust protection against oxidative stress and inflammation.

Inhibition of the NF-κB Pro-Inflammatory Pathway

Concurrent with its activation of the Nrf2 system, bardoxolone methyl is also a potent inhibitor of the Nuclear Factor-kappa B (NF-κB) signaling pathway, a central mediator of inflammation.[1] The NF-κB family of transcription factors plays a crucial role in the immune response by driving the expression of genes involved in inflammation, cell survival, and proliferation. Dysregulation of this pathway is implicated in numerous chronic inflammatory diseases and cancers.[4]

The mechanism of NF-κB inhibition by bardoxolone methyl is also mediated by its reactive chemical structure. The molecule directly targets and inhibits the IκB kinase (IKK) complex, specifically the IKKβ subunit.[2] In the canonical NF-κB pathway, inflammatory stimuli (such as tumor necrosis factor or interleukin-1β [IL-1β]) activate the IKK complex. Activated IKKβ then phosphorylates the inhibitory protein IκBα, which is bound to the NF-κB dimer (typically p65/p50) in the cytoplasm. This phosphorylation event signals IκBα for ubiquitination and proteasomal degradation, which liberates the NF-κB dimer.[4] Once freed, NF-κB translocates to the nucleus, where it binds to promoter regions of target genes and initiates their transcription.

Bardoxolone methyl disrupts this cascade by binding to a critical cysteine residue (Cys-179) in the activation loop of IKKβ, preventing its activation.[10] By inhibiting IKKβ, bardoxolone methyl blocks the phosphorylation and subsequent degradation of IκBα. This effectively "locks" the NF-κB dimer in an inactive state in the cytoplasm, preventing its nuclear translocation and the transcription of its target genes.[4] This inhibitory action leads to the suppression of a wide range of pro-inflammatory and pro-proliferative gene products, including inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), various cytokines and chemokines, and cell cycle regulators like cyclin D1.[3] This potent anti-inflammatory activity was the primary rationale for its initial investigation as a treatment for cancer.[2]

Interplay of Pathways and Other Molecular Targets

The Nrf2 and NF-κB pathways do not operate in isolation; there is significant functional cross-talk between them. Activation of the Nrf2 pathway can exert an inhibitory effect on NF-κB signaling, providing a secondary, indirect mechanism for bardoxolone methyl's anti-inflammatory effects.[15] Beyond these two primary targets, research has suggested that bardoxolone methyl interacts with other cellular proteins. Some studies have identified it as an antagonist of the peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor involved in metabolism and inflammation.[2] In certain cancer cell lines, it has also been shown to induce the degradation of the epidermal growth factor receptor (EGFR) in a Keap1-dependent manner.[6] More recently, in vitro studies have demonstrated that bardoxolone methyl can inhibit the replication of SARS-CoV-2 by targeting the viral 3CL protease, which spurred exploratory interest in its potential use for COVID-19.[1]

The very chemical feature that makes bardoxolone methyl a highly potent modulator of these pathways—its electrophilic nature—is also a source of potential liability. The Michael addition reaction that enables its binding to cysteine residues on Keap1 and IKKβ is a powerful but not perfectly specific interaction. While the unique stereochemistry of the triterpenoid scaffold provides some degree of selectivity, such a reactive molecule has the potential to interact with other cysteine-containing proteins throughout the body. This chemical promiscuity may explain the emergence of unexpected, off-target toxicities observed during its clinical development. For instance, the severe cardiovascular adverse events seen in the BEACON trial were later linked to modulation of the endothelin signaling pathway, a system rich in cysteine-containing proteins that could serve as alternative targets for the drug.[19] Similarly, the consistent signal of hepatotoxicity, manifested as elevated liver transaminases, could arise from off-target interactions with critical metabolic enzymes in the liver.[1] This creates a fundamental tension: the chemical reactivity essential for its desired high potency is inextricably linked to a risk of off-target effects, a challenge that ultimately proved insurmountable in its clinical development.

Clinical Development Trajectory: From Oncology to Nephrology

The clinical development of bardoxolone methyl followed an unconventional path, beginning with investigations in oncology before a serendipitous discovery prompted a complete strategic pivot to the field of nephrology.

Initial Investigations in Oncology

Bardoxolone methyl was first brought into the clinic based on its potent anti-inflammatory and anti-proliferative properties, with the primary goal of developing a novel cancer therapeutic.[3] The initial first-in-human Phase 1 clinical trial (NCT00649231) enrolled adult patients with advanced solid tumors or lymphoid malignancies who were refractory to standard therapies.[1] The study was designed to establish the drug's safety profile, determine the maximum tolerated dose (MTD), and look for early signals of antitumor activity.[22]

The trial established an MTD of 900 mg administered orally once daily.[1] The dose-limiting toxicity (DLT) was identified as Grade 3 reversible elevations in liver transaminases (AST/ALT), a finding that would persist as a key safety signal throughout the drug's development.[1] Pharmacodynamic assessments confirmed that the drug was engaging its intended targets in humans. Measurements in peripheral blood mononuclear cells (PBMCs) showed a significant increase in the mRNA levels of NQO1, a downstream target of Nrf2, confirming activation of the antioxidant pathway.[1] Furthermore, analyses of tumor biopsy samples showed decreased levels of NF-κB and cyclin D1, consistent with inhibition of the pro-inflammatory pathway.[1] Encouragingly, objective tumor responses were observed, including a complete response in a patient with mantle cell lymphoma and a partial response in a patient with anaplastic thyroid carcinoma, supporting the drug's potential as an anti-neoplastic agent.[22]

The Serendipitous Pivot to Chronic Kidney Disease (CKD)

A pivotal and unexpected observation emerged from this initial oncology trial: a majority of the cancer patients treated with bardoxolone methyl exhibited a consistent and statistically significant improvement in their kidney function, as measured by an increase in their estimated glomerular filtration rate (eGFR).[1] At the time, this was a surprising finding in a trial focused on cancer.

This observation, however, was quickly contextualized within the growing understanding of the pathophysiology of chronic kidney disease. The progression of CKD, particularly diabetic kidney disease, is known to be driven by chronic inflammation and persistent oxidative stress, the very pathways targeted by bardoxolone methyl.[2] The drug's dual mechanism of activating the protective Nrf2 pathway while suppressing the damaging NF-κB pathway provided a compelling biological rationale for the observed eGFR improvement.[1] This serendipitous clinical signal was so strong that it prompted the developer, Reata Pharmaceuticals, to undertake a major strategic pivot, shifting the entire focus of the bardoxolone methyl development program away from the competitive oncology landscape and toward the significant unmet medical need in nephrology.[1]

Key Corporate Stakeholders and Collaborations

The extensive and costly clinical development program for bardoxolone methyl, particularly in CKD, was managed by a consortium of pharmaceutical companies.

• Reata Pharmaceuticals, a Texas-based biopharmaceutical company, was the originator and primary developer of the drug, sponsoring the initial trials and leading the overall strategy.[1]
• To fund and execute the large, global Phase 2 and Phase 3 trials required for CKD, Reata formed strategic partnerships with major pharmaceutical companies. AbbVie (then Abbott Laboratories) was a key collaborator, co-funding and co-managing the development program for several years.[1] Biogen (formerly Biogen Idec) also became a major partner, particularly as a sponsor for the pivotal BEACON trial.[24]
• For development and commercialization in Japan and other Asian territories, Reata partnered with Kyowa Kirin (formerly Kyowa Hakko Kirin).[1] This collaboration was responsible for running parallel clinical trials in Japanese populations, including the TSUBAKI and AYAME studies.
• Later in its lifecycle, after the primary CKD programs had faced setbacks, the UK-based company e-Therapeutics announced it was exploring the potential of bardoxolone methyl as an antiviral treatment for COVID-19, though this did not advance to late-stage trials.[1]

Analysis of Major Clinical Trials in Chronic Kidney Disease

The clinical evaluation of bardoxolone methyl in chronic kidney disease was extensive, marked by initial promising results that ultimately gave way to significant safety concerns and a failure to demonstrate benefit on hard clinical outcomes. The trajectory of these trials tells a story of the challenges in translating a potent pharmacological effect on a surrogate marker into a meaningful therapeutic advance.

The BEAM Study (Phase 2): Fueling Initial Optimism

The BEAM (Bardoxolone Methyl Treatment: Renal Function in CKD/Type 2 Diabetes) study was a Phase 2, multi-center, randomized, placebo-controlled trial that served as the primary proof-of-concept for bardoxolone methyl in nephrology.[1] The trial enrolled 227 patients with moderate-to-severe CKD (eGFR between 20 and 45 ml/min/1.73

m2) and type 2 diabetes.[1] The primary objective was to assess the change in eGFR after 24 weeks of treatment, with a follow-up period extending to 52 weeks.

The results of the BEAM study were highly encouraging and generated significant excitement in the nephrology community. The trial met its primary endpoint, with patients randomized to bardoxolone methyl experiencing a statistically significant and clinically substantial mean increase in eGFR compared to a slight decline in the placebo group.[1] At 24 weeks, the mean increases in eGFR for the 25 mg, 75 mg, and 150 mg dose groups were 8.2, 11.4, and 10.4 ml/min/1.73

m2, respectively, relative to placebo.[28] This improvement was sustained through 52 weeks of treatment.[29]

The safety profile in BEAM was described as generally manageable. The most frequently reported adverse event was muscle spasms, which were typically mild to moderate in severity.[1] However, other safety signals were present, including a notable dose-dependent weight loss, higher rates of hypomagnesemia, and transient elevations in liver transaminases, consistent with the drug's known pharmacology.[16] Despite these signals, the robust eGFR improvement was seen as a highly promising result, providing the impetus to move rapidly into a large-scale Phase 3 outcomes trial.

The BEACON Study (Phase 3): The Pivotal Trial and Its Failure

Building on the success of BEAM, Reata and its partners launched the BEACON (Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events) trial (NCT01351675).[25] This was a large, multinational Phase 3 RCT designed to provide definitive evidence of the drug's benefit. The study enrolled over 2,000 patients with advanced (Stage 4) CKD and type 2 diabetes, a population at very high risk for progression to kidney failure.[1] Unlike BEAM, which used the surrogate marker of eGFR as its primary endpoint, BEACON was designed to assess the effect of bardoxolone methyl on a hard composite clinical endpoint: the time to first occurrence of end-stage renal disease (ESRD, defined as the need for chronic dialysis or kidney transplant) or cardiovascular death.[25]

In October 2012, the development program suffered a catastrophic setback when the BEACON trial was terminated prematurely.[1] The decision was made on the recommendation of the trial's independent data monitoring committee, which identified a significant safety imbalance. Patients in the bardoxolone methyl arm were experiencing a statistically significant and unacceptable increase in the rate of serious heart-related adverse events, including hospitalizations for heart failure, as well as an excess of cardiovascular deaths, compared to the placebo group.[1]

Subsequent post-hoc analyses conducted by the sponsors sought to understand the mechanism behind this unexpected cardiotoxicity. The findings strongly suggested that the heart failure events were not due to direct myocardial toxicity but were instead a consequence of drug-induced fluid overload.[19] These events tended to occur early in the treatment course and were associated with rapid weight gain and peripheral edema in some patients. The analyses identified two key baseline predictors of risk: a prior history of hospitalization for heart failure and an elevated level of B-type natriuretic peptide (BNP), a biomarker of cardiac strain and fluid retention.[1] The proposed pharmacological mechanism for this adverse effect was bardoxolone methyl-induced sodium and volume retention, potentially mediated through off-target modulation of the endothelin signaling pathway in the kidney.[19] The failure of the BEACON trial was a major blow to the program and cast serious doubt on the future of the drug.

The CARDINAL Study (Phase 2/3): A New Indication and Lingering Questions

Following the failure of BEACON, the development strategy was re-focused on rare forms of kidney disease where the benefit-risk calculation might be different and where the patient population might be less susceptible to fluid-related adverse events. This led to the initiation of the CARDINAL trial (NCT03019185), a Phase 2/3 study in adolescent and adult patients (ages 12 to 70) with CKD caused by Alport syndrome, a rare, progressive genetic disorder that leads to kidney failure.[32]

The CARDINAL trial's design was critically important, as it was specifically structured to address the key question that arose from the BEACON failure: was the eGFR increase a true, durable modification of disease progression, or was it merely a transient hemodynamic effect? To answer this, the trial included two primary efficacy endpoints based on the change in eGFR from baseline while patients were on treatment (at weeks 48 and 100). Crucially, it also included key secondary endpoints that measured the change in eGFR after a 4-week off-treatment (washout) period (at weeks 52 and 104).[23]

The results were complex and ultimately unconvincing to regulators.

• On-Treatment Efficacy: The trial met its primary endpoints. Patients treated with bardoxolone methyl showed a statistically significant preservation of eGFR compared to the placebo group at both Week 48 and Week 100, with a between-group difference of 9.2 and 7.4 ml/min/1.73 m2, respectively.[33]
• Off-Treatment Efficacy: The results from the washout periods were far less clear. After the 4-week off-treatment period, the substantial eGFR benefit observed on-treatment was largely reversed. At Week 52, a small but statistically significant difference of 5.4 ml/min/1.73 m2 remained.[33] However, at the end of the study at Week 104, the off-treatment difference was smaller (4.4 ml/min/1.73 m2) and, in a post-hoc analysis that did not impute missing data, was no longer statistically significant.[33] This failure to demonstrate a robust, durable benefit after drug withdrawal was a critical weakness.

The safety profile in CARDINAL also raised concerns. Treatment discontinuations were more common in the bardoxolone methyl group, frequently due to protocol-specified elevations in liver transaminases.[33] Furthermore, treatment was associated with a significant increase in the urinary albumin-to-creatinine ratio (UACR), a marker of kidney damage.[21] This paradoxical finding, where a drug increased eGFR while also increasing albuminuria, lent strong support to the hypothesis that bardoxolone methyl was inducing a state of glomerular hyperfiltration—a potentially harmful hemodynamic stress on the kidney.

The TSUBAKI, FALCON, and AYAME Studies: The Final Chapter

Several other key studies were conducted in the final stages of the drug's development.

• TSUBAKI (Phase 2): This was a Japanese study (NCT02316821) designed to rigorously confirm the eGFR effect. By using the gold-standard inulin clearance method for measuring GFR, the TSUBAKI study demonstrated that bardoxolone methyl does cause a true increase in measured GFR, ruling out the possibility that the effect was merely an artifact of its impact on serum creatinine secretion or metabolism.[16]
• FALCON (Phase 3): This large trial (NCT03918447) was initiated to study the drug's effects in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), another genetic cause of CKD.[36] However, the trial was terminated early on May 10, 2023, before its completion.[38]
• AYAME (Phase 3): This large, long-term outcomes study was conducted by Kyowa Kirin in Japan in over 1,000 patients with diabetic kidney disease. The results of this trial were the definitive conclusion to the bardoxolone methyl story. The study met its primary composite endpoint, which was the time to a ≥30% decrease in eGFR from baseline or the onset of ESKD. However, this positive result was driven entirely by the "soft" eGFR component of the endpoint. Critically, when the "hard" clinical outcome of ESKD was analyzed alone, there was no difference in the rate of events between the bardoxolone methyl and placebo groups.[39]

The unambiguous finding from the AYAME trial—that years of treatment with bardoxolone methyl did not prevent patients from progressing to dialysis or needing a kidney transplant—was the final confirmation that the drug's effect on the surrogate marker of eGFR did not translate into a meaningful clinical benefit. Based on these results, Reata Pharmaceuticals and Kyowa Kirin announced the discontinuation of the entire clinical development program for bardoxolone, leading to the termination of the ongoing FALCON and EAGLE (extended access) trials.[39]

The entire clinical journey of bardoxolone methyl in CKD serves as a powerful illustration of the "surrogate endpoint trap." The program was built on the drug's ability to raise eGFR, a logical but unproven surrogate for long-term renal protection in this context. The BEACON trial provided the first major warning that this eGFR increase was not only failing to prevent adverse cardiovascular outcomes but was associated with an increase in them. The design of the CARDINAL trial, with its washout period, directly tested the durability of the eGFR effect, and the results suggested it was largely a transient pharmacodynamic phenomenon. The AYAME trial provided the final, conclusive evidence, demonstrating a complete disconnect between the drug's effect on the surrogate (eGFR decline) and its lack of effect on the true clinical outcome (ESKD). This stands in stark contrast to other successful therapies in nephrology, such as SGLT2 inhibitors, which often cause an initial, acute drop in eGFR but provide profound long-term cardiorenal protection. The bardoxolone saga underscores the critical principle that not all changes in a surrogate marker are indicative of a true clinical benefit, a lesson of profound importance for future drug development in nephrology.

Trial Name	Phase	Indication	Patient Population (N)	Primary Endpoint(s)	Key Efficacy Outcome	Key Safety Outcome/Reason for Discontinuation
BEAM	2	CKD with Type 2 Diabetes	227	Change in eGFR at 24 weeks	Significant increase in eGFR vs. placebo	Generally manageable; muscle spasms, weight loss, hypomagnesemia
BEACON	3	Stage 4 CKD with Type 2 Diabetes	~2,185	Time to ESRD or CV death	-	Terminated early due to significant increase in heart failure hospitalizations and CV death
CARDINAL	2/3	CKD with Alport Syndrome	157	Change in eGFR at 48 & 100 weeks	Significant on-treatment eGFR preservation; benefit largely lost after 4-week washout	Increased liver transaminases, increased albuminuria
AYAME	3	Diabetic Kidney Disease	1,013	Time to ≥30% eGFR decline or ESKD	Met composite endpoint, but showed no benefit on the hard endpoint of ESKD	No new safety signals; development discontinued due to lack of efficacy on hard endpoint

Comprehensive Safety and Tolerability Profile

The clinical development of bardoxolone methyl was ultimately halted not only due to questions about its efficacy but also because of a complex and concerning safety profile that emerged over the course of multiple large-scale trials. The risks associated with the drug proved to be a significant barrier to establishing a favorable benefit-risk balance.

Cardiovascular Risk: Heart Failure and Fluid Overload

The most severe and trial-limiting safety issue for bardoxolone methyl was its association with an increased risk of cardiovascular events, specifically heart failure. This risk was most starkly demonstrated in the Phase 3 BEACON trial, which was terminated prematurely because of a significantly higher rate of hospitalizations for heart failure and cardiovascular deaths in patients receiving the drug compared to placebo.[1]

Detailed post-hoc analyses of the BEACON data concluded that these events were primarily driven by pharmacologically-induced fluid and sodium retention, leading to acute fluid overload in susceptible individuals.[19] A substudy of BEACON patients showed that those treated with bardoxolone methyl had a clinically meaningful reduction in 24-hour urine volume and sodium excretion at Week 4, providing direct evidence of an anti-natriuretic effect.[19] The clinical presentation was similar to that observed with endothelin receptor antagonists in patients with advanced CKD, and preclinical data suggested that bardoxolone methyl modifies endothelin signaling, providing a plausible biological mechanism for this adverse effect.[19] Consequently, the drug is considered particularly dangerous for individuals with a history of heart disease or elevated baseline biomarkers of fluid retention, such as BNP.[1]

Hepatotoxicity and Transaminase Elevations

A consistent and well-documented safety signal across the entire development program, from the earliest Phase 1 oncology trials to the final CKD studies, was the occurrence of reversible, dose-dependent elevations in liver transaminases (ALT and AST).[1] This was the dose-limiting toxicity in the first-in-human study and remained a frequent adverse event in all subsequent trials.[22]

In the CARDINAL trial, for example, an increase in liver enzymes was observed in a striking 90.9% of bardoxolone-treated patients, and these elevations were a common reason for dose reduction or permanent treatment discontinuation.[21] While these events were typically asymptomatic, transient, and reversible upon drug cessation, and were not associated with cases of severe drug-induced liver injury (i.e., no Hy's law cases were reported), the high frequency of this signal necessitated intensive laboratory monitoring and represented a significant clinical management challenge.[38]

Renal Parameters of Concern

Paradoxically for a drug being developed to treat kidney disease, bardoxolone methyl raised several concerns related to its effects on key renal parameters.

• Increased Albuminuria: Across multiple studies, including BEACON and CARDINAL, treatment with bardoxolone methyl was associated with a significant increase in the urinary albumin-to-creatinine ratio (UACR).[21] This is a highly concerning finding, as albuminuria is a cardinal sign of glomerular damage and a strong independent predictor of CKD progression and cardiovascular risk. This effect ran directly counter to the goals of nephroprotective therapy and lent strong support to the hypothesis that the drug's eGFR-boosting effect was due to a potentially maladaptive increase in intraglomerular pressure and hyperfiltration, which could accelerate long-term kidney damage.[35]
• Increased Blood Pressure: Some studies also reported an association between bardoxolone methyl treatment and increases in systolic and diastolic blood pressure.[19] As hypertension is a primary driver of CKD progression, this was another unfavorable effect that complicated the drug's overall risk profile.

Commonly Reported Adverse Events

Beyond the major organ-specific toxicities, a consistent pattern of other adverse events was reported across the clinical trial program.

• Muscle Spasms: This was the most frequently reported adverse event in many trials, including BEAM and FALCON.[1] While generally described as mild to moderate in severity and not associated with laboratory evidence of rhabdomyolysis, its high incidence (affecting up to 49% of patients in the FALCON trial) represented a significant tolerability issue.[38]
• Weight Loss: A notable and significant decrease in body weight was consistently observed in patients treated with bardoxolone methyl compared to placebo.[16] While potentially beneficial in some patient populations, this raised concerns about the possibility of muscle wasting or catabolism. This was particularly relevant as a loss of muscle mass would lead to reduced production of creatinine, which could artificially lower serum creatinine levels and thereby confound and inflate the calculation of eGFR, potentially overstating the drug's true effect on kidney function.[28]
• Gastrointestinal Effects: Nausea, vomiting, and diarrhea were common, particularly during the initiation and dose-escalation phases of treatment.[16]
• Hypomagnesemia: A consistent laboratory finding was a decrease in serum magnesium levels, which was reported as an adverse event in a subset of patients.[16]

Regulatory Scrutiny and Global Market Access

After years of extensive clinical investigation, the fate of bardoxolone methyl was ultimately decided by regulatory agencies in key global markets. The complex efficacy data, dominated by a surrogate endpoint that failed to translate into hard clinical outcomes, coupled with a significant safety profile, led to a consensus of non-approval from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The U.S. FDA Complete Response Letter for Alport Syndrome

Following the completion of the CARDINAL trial, Reata Pharmaceuticals submitted a New Drug Application (NDA) to the FDA seeking approval for bardoxolone methyl for the treatment of CKD caused by Alport syndrome.[44] The application was reviewed by the FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) on December 8, 2021. The committee meeting resulted in a decisive and unanimous vote (13 to 0) against recommending approval, with members expressing significant doubts about the drug's efficacy and concerns about its safety profile.[1]

On February 25, 2022, the FDA formalized this position by issuing a Complete Response Letter (CRL).[45] A CRL indicates that the agency has completed its review of the application and has decided that it cannot be approved in its present form. The FDA's rationale, as outlined in the CRL and the preceding advisory committee briefing documents, was multi-faceted:

• Lack of Demonstrated Efficacy: The agency concluded that the submitted data failed to demonstrate that bardoxolone methyl was effective in slowing the progression of kidney function loss in patients with Alport syndrome.[45] The FDA was not convinced that the observed "on-treatment" improvement in eGFR represented a true, durable effect on the course of the disease. The substantial reversal of the eGFR benefit during the 4-week washout period was a key point of contention, suggesting the effect was primarily pharmacodynamic and not indicative of a structural or functional preservation of the kidney.[29]
• Unfavorable Benefit-Risk Balance: The FDA and its advisors weighed the questionable efficacy against the known risks. Concerns were raised about the drug's long-term safety, particularly its effects on increasing albuminuria and blood pressure, both of which are associated with worse renal outcomes.[43]
• Path Forward: The FDA stated that to resolve the deficiencies, the sponsor would need to conduct a new, adequate, and well-controlled clinical trial that could provide convincing evidence of a clinically relevant effect on either the rate of kidney function loss or on a hard clinical outcome.[45]

The European Medicines Agency (EMA) Application Withdrawal

A similar regulatory process unfolded in Europe. Reata submitted a Marketing Authorisation Application (MAA) to the EMA for bardoxolone methyl, under the proposed trade name Imbarkyd, for the same indication of CKD in Alport syndrome.[26] However, the application did not proceed to a final decision.

On November 9, 2022, Reata formally withdrew its application from the EMA.[50] This withdrawal was not voluntary in a strategic sense but was made after the EMA's Committee for Medicinal Products for Human Use (CHMP) had communicated its provisional opinion that the drug could not be authorized based on the data provided.[50] The EMA's unresolved concerns were substantial and mirrored those of the FDA, focusing on three key areas [50]:

1. Metabolism and Safety of Metabolites: The agency was not satisfied with the information provided on how the drug is metabolized in the body and whether its end products could pose a health risk to patients.
2. Lack of Convincing Efficacy: The CHMP concluded that the main study did not convincingly demonstrate a sustained, beneficial effect of bardoxolone methyl on kidney function in patients with Alport syndrome.
3. Cardiorenal Safety Concerns: The agency had outstanding concerns about potential negative long-term effects on both kidney and heart function.

Ultimately, the EMA's provisional opinion was that the benefits of Imbarkyd did not outweigh its risks, leading the company to withdraw the application to pre-empt a formal negative opinion.[50]

Status in Other Jurisdictions

• Japan: Reata's partner, Kyowa Kirin, had submitted a marketing application in Japan for the treatment of Alport syndrome in July 2021.[26] However, following the definitive negative results of the AYAME trial in diabetic kidney disease, which showed a lack of benefit on hard renal outcomes, the companies jointly decided to cease all clinical development of bardoxolone in May 2023.[39] This decision effectively ended any path to approval in Japan as well.
• Orphan Drug Designation: It is noteworthy that bardoxolone methyl had successfully obtained Orphan Drug Designation for the treatment of Alport syndrome and ADPKD from both the FDA and the EMA.[3] This status provides regulatory and financial incentives to encourage the development of drugs for rare diseases. However, this case clearly demonstrates that orphan designation is no guarantee of final approval; the drug must still meet the statutory standards for safety and efficacy.

Synthesis, Context, and Future Outlook

The Promise and Peril of a Potent Nrf2 Activator

The story of bardoxolone methyl is a powerful case study in the complexities of drug development, highlighting the profound gap that can exist between a promising biological mechanism and a successful clinical therapeutic. On paper, the drug's dual action as a potent activator of the cytoprotective Nrf2 pathway and an inhibitor of the pro-inflammatory NF-κB pathway presented an elegant and compelling strategy to combat diseases driven by oxidative stress and inflammation, such as chronic kidney disease. This strong scientific rationale fueled over a decade of intensive clinical research and substantial financial investment.

However, the clinical reality proved far more complex. The very chemical reactivity that endowed the molecule with its high potency also appears to have contributed to a profile of off-target effects and significant safety liabilities, most notably the risk of fluid overload and heart failure in susceptible patients. Furthermore, the drug's primary biological effect on the kidney—a significant increase in eGFR—ultimately failed to translate into the most important clinical outcomes for patients: the prevention of end-stage kidney disease and cardiovascular death. This disconnect between the modulation of a surrogate endpoint and the improvement of hard clinical outcomes became the central, insurmountable challenge that led to the program's downfall. Bardoxolone methyl thus serves as a stark reminder that even a potent and well-characterized mechanism of action does not guarantee a favorable benefit-risk profile in a complex, multifactorial disease.

Context: The Unmet Need and Standard of Care in Alport Syndrome and CKD

The pursuit of bardoxolone methyl was driven by a significant unmet medical need in nephrology. For patients with Alport syndrome, there are still no approved disease-specific therapies.[56] The standard of care remains supportive, centered on the use of renin-angiotensin-aldosterone-system (RAAS) inhibitors, such as ACE inhibitors and ARBs, to control blood pressure and reduce proteinuria, thereby slowing the inexorable progression towards ESKD.[56] Given that many patients, particularly males, still face kidney failure at a young age, the demand for a novel therapy that could fundamentally alter the disease course is immense.[57]

In the broader landscape of chronic kidney disease, particularly diabetic kidney disease, the standard of care has evolved significantly during the time bardoxolone methyl was in development. While RAAS inhibitors remain a cornerstone of therapy, the emergence of two new classes of drugs—sodium-glucose cotransporter-2 (SGLT2) inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs) like finerenone—has revolutionized treatment.[61] These agents have demonstrated robust, consistent benefits on both hard renal outcomes (slowing GFR decline, reducing progression to ESKD) and cardiovascular outcomes in large-scale clinical trials.

The concurrent failure of bardoxolone methyl and the success of SGLT2 inhibitors provide a particularly instructive contrast. Bardoxolone methyl caused a large, acute increase in eGFR but was associated with worse cardiovascular outcomes. SGLT2 inhibitors, conversely, cause a small, acute decrease in eGFR upon initiation but provide profound and durable long-term cardiorenal protection. This comparison powerfully illustrates that the quality and underlying mechanism of a drug's effect on renal hemodynamics are critically important, and that a simple increase in a surrogate marker like eGFR is not, by itself, a reliable predictor of clinical benefit.

Lessons for Future Drug Development in Nephrology

The bardoxolone methyl saga offers several critical lessons for the future of drug development in nephrology and other chronic diseases.

• Beyond Surrogate Endpoints: The primary lesson is the inherent risk of building a development program around a surrogate endpoint, like eGFR, whose link to long-term clinical outcomes has not been definitively established for the specific therapeutic mechanism. Regulators have demonstrated, through their decisions on bardoxolone methyl, that they will apply intense scrutiny to such data, especially when accompanied by safety concerns. Future programs will need to either use validated surrogates or be designed from the outset to demonstrate a clear benefit on hard clinical outcomes.
• The Importance of Patient Selection: The BEACON trial underscored the critical need for careful patient selection. The identification of baseline BNP and prior heart failure as major risk factors for bardoxolone-induced fluid overload highlights that a drug's safety profile can vary dramatically across different subpopulations. Future trials may need more refined inclusion/exclusion criteria to mitigate predictable risks.
• Comprehensive Pharmacological Understanding: The emergence of unexpected adverse events related to fluid retention and the endothelin pathway emphasizes the necessity of a deep and comprehensive understanding of a drug's full pharmacological profile, including potential off-target effects. A narrow focus on the primary mechanism of action can obscure significant liabilities.

The Future of Bardoxolone Methyl and Nrf2 Activation

The clinical development of bardoxolone methyl for chronic kidney disease is effectively concluded. Following the definitive results of the AYAME trial and the subsequent regulatory rejections, the sponsors announced the discontinuation of all ongoing studies in May 2023.[39]

Despite this specific failure, the Nrf2 pathway remains a scientifically valid and highly attractive therapeutic target for a wide range of diseases characterized by inflammation and oxidative stress. The challenge for the pharmaceutical industry will be to leverage the lessons learned from bardoxolone methyl to develop a new generation of Nrf2 activators. The goal will be to design molecules that can harness the therapeutic benefits of this pathway while avoiding the specific chemical liabilities and unfavorable off-target effects that plagued bardoxolone methyl. This may involve exploring different chemical scaffolds, alternative binding sites, or more nuanced mechanisms of pathway modulation to achieve a better balance of efficacy and safety. Meanwhile, the search for effective treatments for Alport syndrome and other forms of CKD continues, with other investigational agents such as atrasentan, finerenone, and novel cell and gene therapies currently under evaluation.[62]

Works cited

1. Bardoxolone methyl - Wikipedia, accessed September 14, 2025, https://en.wikipedia.org/wiki/Bardoxolone_methyl
2. Bardoxolone methyl | 218600-53-4 - ChemicalBook, accessed September 14, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB22514853.htm
3. Bardoxolone Methyl | C32H43NO4 | CID 400769 - PubChem, accessed September 14, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Bardoxolone-methyl
4. Bardoxolone methyl | RTA402 | CDDO-Me | CAS#218600-53-4 | MedKoo Biosciences, accessed September 14, 2025, https://www.medkoo.com/products/5038
5. Definition of bardoxolone methyl - NCI Drug Dictionary, accessed September 14, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bardoxolone-methyl
6. CDDO methyl ester (CAS 218600-53-4) - Cayman Chemical, accessed September 14, 2025, https://www.caymanchem.com/product/11883/cddo-methyl-ester
7. BARDOXOLONE METHYL - precisionFDA, accessed September 14, 2025, https://precision.fda.gov/ginas/app/ui/substances/f7847f84-fcca-4ceb-aa53-4dca93fed820
8. Compound: BARDOXOLONE METHYL (CHEMBL1762621) - ChEMBL - EMBL-EBI, accessed September 14, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1762621
9. Bardoxolone methyl: Uses, Interactions, Mechanism of Action ..., accessed September 14, 2025, https://go.drugbank.com/drugs/DB05983
10. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties - PMC, accessed September 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4211867/
11. BARDOXOLONE METHYL - New Drug Approvals, accessed September 14, 2025, https://newdrugapprovals.org/2014/03/04/bardoxolone-upcoming-blockbuster/
12. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its | DDDT, accessed September 14, 2025, https://www.dovepress.com/bardoxolone-methyl-cddo-me-as-a-therapeutic-agent-an-update-on-its-pha-peer-reviewed-fulltext-article-DDDT
13. Bardoxolone methyl|IKK inhibitor, potent antioxidant inflammation modulator - APExBIO, accessed September 14, 2025, https://www.apexbt.com/bardoxolone-methyl.html
14. Bardoxolone: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 14, 2025, https://go.drugbank.com/drugs/DB12651
15. Bardoxolone Methyl: A Comprehensive Review of Its Role as a Nrf2 Activator in Anticancer Therapeutic Applications - MDPI, accessed September 14, 2025, https://www.mdpi.com/1424-8247/18/7/966
16. Bardoxolone methyl: drug development for diabetic kidney disease - PMC - PubMed Central, accessed September 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7497696/
17. Bardoxolone Methyl | IκB/IKK inhibitor | 99.86%(HPLC) | In Stock - Selleck Chemicals, accessed September 14, 2025, https://www.selleckchem.com/products/bardoxolone-methyl.html
18. Bardoxolone methyl (RTA 402) | Nrf2 Activator - MedchemExpress.com, accessed September 14, 2025, https://www.medchemexpress.com/Bardoxolone-methyl.html
19. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl - PubMed, accessed September 14, 2025, https://pubmed.ncbi.nlm.nih.gov/24903467/
20. Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl - Karger Publishers, accessed September 14, 2025, https://karger.com/ajn/article/39/6/499/41414/Mechanisms-Contributing-to-Adverse-Cardiovascular
21. The CARDINAL Trial of Bardoxolone Methyl in Alport Syndrome: When Marketing Interests Prevail over Patients Clinical Needs - PubMed, accessed September 14, 2025, https://pubmed.ncbi.nlm.nih.gov/36731435/
22. A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas | Clinical Cancer Research - AACR Journals, accessed September 14, 2025, https://aacrjournals.org/clincancerres/article/18/12/3396/179699/A-Phase-I-First-in-Human-Trial-of-Bardoxolone
23. Bardoxolone in Alport Syndrome: The CARDINAL trial - NephJC, accessed September 14, 2025, http://www.nephjc.com/news/bardoxolone
24. Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes | ClinicalTrials.gov, accessed September 14, 2025, https://clinicaltrials.gov/study/NCT01551446
25. Study Details | NCT01351675 | Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes | ClinicalTrials.gov, accessed September 14, 2025, https://www.clinicaltrials.gov/study/NCT01351675
26. Bardoxolone, A New Oral Nrf2 Activator, Applies For Listing in The ..., accessed September 14, 2025, https://www.hsppharma.com/news/bardoxolone-a-new-oral-nrf2-activator-applie-51411633.html
27. NCT02316821 | The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes - ClinicalTrials.gov, accessed September 14, 2025, https://clinicaltrials.gov/study/NCT02316821
28. The Extinguished Beacon of Bardoxolone: Not a Monday Morning Quarterback Story - PMC, accessed September 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3725304/
29. Bardoxolone for CKD: The Paradox of Confusion and Dogma - PMC, accessed September 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9717645/
30. Reata and Abbott Halt Phase 3 BEACON Trial For Bardoxolone Methyl Amid Serious Safety Concerns - diaTribe.org, accessed September 14, 2025, https://diatribe.org/diabetes-research/reata-and-abbott-halt-phase-3-beacon-trial-bardoxolone-methyl-amid-serious-safety
31. Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study) - PMC - PubMed Central, accessed September 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7271944/
32. Health Technology Briefing June 2022 - NIHR Innovation Observatory, accessed September 14, 2025, https://www.io.nihr.ac.uk/wp-content/uploads/2022/06/23812-TSID_9998-Bardoxolone-Methyl-for-Alport-Syndrome-V1.0-JUN2020-NON-CONF.pdf
33. Effects of Bardoxolone Methyl in Alport Syndrome - National Institutes of Health (NIH) |, accessed September 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9718021/
34. A Phase 2/3 Study of Bardoxolone Methyl in Patients with Alport Syndrome - American Society of Nephrology | Kidney Week - Abstract Details (2017), accessed September 14, 2025, https://www.asn-online.org/education/kidneyweek/2017/program-abstract.aspx?controlId=2830903
35. The CARDINAL Trial of Bardoxolone Methyl in Alport Syndrome: When Marketing Interests Prevail over Patients Clinical Needs - Karger Publishers, accessed September 14, 2025, https://karger.com/nef/article/147/8/465/835893/The-CARDINAL-Trial-of-Bardoxolone-Methyl-in-Alport
36. A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease | NYU Langone Health, accessed September 14, 2025, https://clinicaltrials.med.nyu.edu/clinicaltrial/1644/phase-3-trial-efficacy/
37. FALCON - NHS Health Research Authority, accessed September 14, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/falcon/
38. A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant, accessed September 14, 2025, https://www.biogentriallink.com/content/dam/global-development/general/biogen-trial-link/educational/en-us/pdf/csr/NCT03918447-Synopsis.pdf
39. Why Did the FALCON Clinical Trial End? - Polycystic kidney disease - PKD Foundation, accessed September 14, 2025, https://pkdcure.org/resources/why-did-the-falcon-clinical-trial-end/
40. 10 May 2023 Subject: Termination of bardoxolone methyl and chronic kidney disease research Dear Alport Syndrome Foundatio, accessed September 14, 2025, https://alportsyndrome.org/wp-content/uploads/2023/05/Bardoxolone-Notification-May-10-2023.pdf
41. Bardoxolone methyl - Alzheimer's Drug Discovery Foundation, accessed September 14, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Bardaloxone-methyl-Cognitive-Vitality-For-Researchers.pdf
42. Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study - Oxford Academic, accessed September 14, 2025, https://academic.oup.com/ndt/article/38/5/1204/6674775
43. FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Cardiovascular and Renal Drugs Advisory Commit, accessed September 14, 2025, https://www.fda.gov/media/154626/download
44. Bardoxolone: What is it and is it FDA approved? - Drugs.com, accessed September 14, 2025, https://www.drugs.com/history/bardoxolone.html
45. FDA Rejects Bardoxolone Methyl For Chronic Kidney Disease - HCPLive, accessed September 14, 2025, https://www.hcplive.com/view/fda-rejects-bardoxolone-methyl-chronic-kidney-disease
46. re: FDA Decision on Bardoxolone Methyl - Alport Syndrome ..., accessed September 14, 2025, https://alportsyndrome.org/re-fda-decision-on-bardoxolone-methyl/
47. FDA Rejects Reata's Bardoxolone as Treatment for Chronic Kidney Disease Caused by Alport Syndrome - Global Genes, accessed September 14, 2025, https://globalgenes.org/raredaily/fda-rejects-reatas-bardoxolone-as-treatment-for-chronic-kidney-disease-caused-by-alport-syndrome/
48. Why did the FDA reject approval of Bardoxolone methyl for chronic kidney disease?, accessed September 14, 2025, https://www.chemicalbook.com/article/why-did-the-fda-reject-approval-of-bardoxolone-methyl-for-chronic-kidney-disease.htm
49. Novel Therapies for Alport Syndrome - PMC, accessed September 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9081811/
50. Imbarkyd | European Medicines Agency (EMA), accessed September 14, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/imbarkyd
51. 20 December 2022 Subject: Alport syndrome EMA Application Withdrawal Dear Alport Syndrome Foundation, This letter is to in, accessed September 14, 2025, https://alportsyndrome.org/wp-content/uploads/2022/12/Reata-Pharmaceuticals-EAGLE-Statement-December-20-2022.pdf
52. accessed January 1, 1970, httpss://www.ema.europa.eu/en/medicines/human/EPAR/imbarkyd
53. Search Orphan Drug Designations and Approvals - FDA, accessed September 14, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=687219
54. EU/3/18/2019 - orphan designation for treatment of Alport syndrome, accessed September 14, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2019
55. Potential Alport Therapy Named Orphan Drug by EU, Phase 3 Trial Enrolling, accessed September 14, 2025, https://alportsyndromenews.com/2018/06/18/bardoxolone-by-reata-named-orphan-drug-in-eu-as-alport-treatment-phase-3-trial-enrolling/
56. Alport Syndrome Treatment - Alport Syndrome Foundation, accessed September 14, 2025, https://alportsyndrome.org/treatment/
57. Alport Syndrome - Symptoms, Causes, Treatment | NORD, accessed September 14, 2025, https://rarediseases.org/rare-diseases/alport-syndrome/
58. Alport syndrome symptoms, treatment and info - Kidney Research UK, accessed September 14, 2025, https://www.kidneyresearchuk.org/conditions-symptoms/alport-syndrome/
59. Alport Syndrome | National Kidney Foundation, accessed September 14, 2025, https://www.kidney.org/kidney-topics/alport-syndrome
60. Alport Syndrome - American Kidney Fund, accessed September 14, 2025, https://www.kidneyfund.org/all-about-kidneys/other-kidney-diseases/alport-syndrome
61. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024, accessed September 14, 2025, https://diabetesjournals.org/care/article/47/Supplement_1/S219/153938/11-Chronic-Kidney-Disease-and-Risk-Management
62. Breakthrough Investigational Medications in Kidney Disease ..., accessed September 14, 2025, https://ocrc.net/breakthrough-investigational-medications-in-kidney-disease-treatment/
63. Experimental Treatments for Alport Syndrome - Alport Syndrome News, accessed September 14, 2025, https://alportsyndromenews.com/experimental-treatments-for-alport-syndrome/
64. Clinical Trials – Active Studies - Alport Syndrome Foundation, accessed September 14, 2025, https://alportsyndrome.org/for-patients/clinical-trials/current-past-clinical-trials/
65. Current and Future Therapeutical Options in Alport Syndrome - MDPI, accessed September 14, 2025, https://www.mdpi.com/1422-0067/24/6/5522